Exelixis : EXEL

All Exelixis Articles

61 Articles

Paul Ausick | Aug 21, 2018 at 4:04 PM EDT

Sears, Exelixis Fall into Tuesday’s 52-Week Low Club

SeaChange, Sears, Exelixis, and Adamis Pharma all posted new 52-week lows Tuesday.

Paul Ausick | Aug 20, 2018 at 4:04 PM EDT

Exelixis, Lannett Topple into Monday’s 52-Week Low Club

Lannett Co., Scorpio Tankers, Mobile Telesystems, and Exelixis all posted new 52-week lows Monday.

Lee Jackson | Apr 18, 2018 at 8:20 AM EDT

4 Red-Hot Biotech Stocks to Buy Before Earnings

These four top Suntrust biotech picks for 2018 all have the potential for big upside moves if they do indeed…

Jon C. Ogg | Feb 27, 2018 at 9:15 AM EST

Top Analyst Upgrades and Downgrades: Albermarle, Best Buy, Chipotle, Exact Sciences, Fitbit, Itron, NuVasive, Palo Alto Networks, Stryker and More

The include Albermarle, Best Buy, Chipotle Mexican Grill, Exact Sciences, Fitbit, Itron, NuVasive, Palo Alto Networks and Stryker.

Chris Lange | Jan 17, 2018 at 11:35 AM EST

Exelixis Slides Despite Positive Late-Stage Results

Shares of Exelixis slipped on Wednesday after the company reported results from its late-stage trial of cabozantinib for advanced hepatocellular…

Chris Lange | Dec 20, 2017 at 1:45 PM EST

Exelixis Wins Big With FDA Approval

Exelixis saw its shares make a handy gain on Wednesday after the company received the nod from the FDA for…

Jon C. Ogg | Dec 20, 2017 at 8:15 AM EST

9 Major Stock Movers to Watch for Wednesday

With tax reform having cleared the Senate and going back to the House, investors were looking for a higher stock…

Chris Lange | Oct 16, 2017 at 9:10 AM EDT

Exelixis Cancer Treatment Hits Key Milestone

Exelixis kicked off the week with a couple updates that are already having a big impact on the stock. These…

Lee Jackson | Oct 6, 2017 at 10:25 AM EDT

4 Biotech Stocks to Buy That May See Huge Volatility From Earnings

Some of the top biotech stocks could become extremely volatile before and after earnings. These four that may be worth…

Lee Jackson | Feb 28, 2017 at 9:30 AM EST

Top Analyst Upgrades and Downgrades: Apple, CVS Health, Priceline, Teva Pharmaceuticals, Workday and Many More

Tuesday’s top analyst upgrades, downgrades and initiations include Apple, CVS Health, Priceline, Teva Pharmaceutical and Workday.

Jon C. Ogg | Nov 3, 2016 at 9:05 AM EDT

Top Analyst Upgrades and Downgrades: Brocade, Facebook, First Solar, Fitbit, ONEOK Partners, Sunrun and More

The top analyst upgrades, downgrades and initiations seen on Thursday morning include Brocade Communications Systems, Facebook, First Solar, Fitbit, ONEOK…

Chris Lange | Oct 10, 2016 at 8:40 AM EDT

Exelixis Continues Massive Run With Positive Cabosun Results

Shares of Exelixis saw a handy gain early Monday morning after the company reported positive results from its mid-stage trial…

Chris Lange | Oct 4, 2016 at 9:15 AM EDT

Key FDA Decisions and Trial Results Expected in October

24/7 Wall St. has collected several big FDA decisions and mid-stage to late-stage trials that should be announced in October.

Chris Lange | Sep 26, 2016 at 10:15 AM EDT

4 Biopharma Companies Moving on Monday Ahead of the Presidential Debate

24/7 Wall St. has picked out some of the major companies in the health care sector that are moving ahead…

Chris Lange | Sep 14, 2016 at 8:20 AM EDT

Key FDA Decisions and Trial Results Coming in the Next 2 Months

24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in…

1 2 3 4 5

Exelixis : EXEL

All Exelixis Articles

Sears, Exelixis Fall into Tuesday’s 52-Week Low Club

Exelixis, Lannett Topple into Monday’s 52-Week Low Club

4 Red-Hot Biotech Stocks to Buy Before Earnings

Top Analyst Upgrades and Downgrades: Albermarle, Best Buy, Chipotle, Exact Sciences, Fitbit, Itron, NuVasive, Palo Alto Networks, Stryker and More

Exelixis Slides Despite Positive Late-Stage Results

Exelixis Wins Big With FDA Approval

9 Major Stock Movers to Watch for Wednesday

Exelixis Cancer Treatment Hits Key Milestone

4 Biotech Stocks to Buy That May See Huge Volatility From Earnings

Top Analyst Upgrades and Downgrades: Apple, CVS Health, Priceline, Teva Pharmaceuticals, Workday and Many More

Top Analyst Upgrades and Downgrades: Brocade, Facebook, First Solar, Fitbit, ONEOK Partners, Sunrun and More

Exelixis Continues Massive Run With Positive Cabosun Results

Key FDA Decisions and Trial Results Expected in October

4 Biopharma Companies Moving on Monday Ahead of the Presidential Debate

Key FDA Decisions and Trial Results Coming in the Next 2 Months

Ripple’s $1.25 Billion Hidden Road Acquisition: One Year On, What’s Changed?

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)

"Did you buy It from the mob?": Dave Ramsey hosts floored by 21-year-old's 30% truck loan

Ripple’s $1.25 Billion Hidden Road Acquisition: One Year On, What’s Changed?

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)

Exelixis : EXEL

All Exelixis Articles

Sears, Exelixis Fall into Tuesday’s 52-Week Low Club

Exelixis, Lannett Topple into Monday’s 52-Week Low Club

4 Red-Hot Biotech Stocks to Buy Before Earnings

Top Analyst Upgrades and Downgrades: Albermarle, Best Buy, Chipotle, Exact Sciences, Fitbit, Itron, NuVasive, Palo Alto Networks, Stryker and More

Exelixis Slides Despite Positive Late-Stage Results

Exelixis Wins Big With FDA Approval

9 Major Stock Movers to Watch for Wednesday

Exelixis Cancer Treatment Hits Key Milestone

4 Biotech Stocks to Buy That May See Huge Volatility From Earnings

Top Analyst Upgrades and Downgrades: Apple, CVS Health, Priceline, Teva Pharmaceuticals, Workday and Many More

Top Analyst Upgrades and Downgrades: Brocade, Facebook, First Solar, Fitbit, ONEOK Partners, Sunrun and More

Exelixis Continues Massive Run With Positive Cabosun Results

Key FDA Decisions and Trial Results Expected in October

4 Biopharma Companies Moving on Monday Ahead of the Presidential Debate

Key FDA Decisions and Trial Results Coming in the Next 2 Months

Ripple’s $1.25 Billion Hidden Road Acquisition: One Year On, What’s Changed?

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Featured Reads

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)

"Did you buy It from the mob?": Dave Ramsey hosts floored by 21-year-old's 30% truck loan